(Q43668313)

English

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

scientific article published in July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Kucuk O

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Fisher E

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Moinpour CM

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Coleman D

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Hussain MH

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sartor AO

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Chatta GS

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Lowe BA

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Eisenberger MA

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Crawford ED

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 July 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

53-58

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Combined androgen blockade for the treatment of metastatic cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The short-form McGill Pain Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The measurement of symptom distress

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring change over time: assessing the usefulness of evaluative instruments.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect sizes for interpreting changes in health status.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901010-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(01)01010-X

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43668313&oldid=2102401399"